GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma

Yung-Kuan Tsou; Kung-Hao Liang; Wey-Ran Lin; Hsien-Kun Chang; Chen-Kan Tseng; Chau-Ting Yeh

doi:10.18632/oncotarget.16253

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma

Yung-Kuan Tsou, Kung-Hao Liang _, Wey-Ran Lin, Hsien-Kun Chang, Chen-Kan Tseng and Chau-Ting Yeh

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:29151-29160. https://doi.org/10.18632/oncotarget.16253

Metrics: PDF 1459 views | HTML 2499 views | ?

Abstract

Yung-Kuan Tsou1, Kung-Hao Liang1,2,3, Wey-Ran Lin1,2,4, Hsien-Kun Chang5, Chen-Kan Tseng6, Chau-Ting Yeh1,2,3,4

1Department of Hepato-Gastroenterology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

2Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan

3Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan

4Chang Gung University, College of Medicine, Taoyuan, Taiwan

5Department of Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

6Department of Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Correspondence to:

Kung-Hao Liang, email: [email protected]

Chau-Ting Yeh, email: [email protected]

Keywords: germline polymorphism, biomarker, cisplatin, gastrointestinal cancer, pharmacogenomics

Received: November 22, 2016 Accepted: February 20, 2017 Published: March 16, 2017

ABSTRACT

Esophageal squamous cell carcinoma is an aggressive cancer. We investigated genetic response predictors for patients with advanced esophageal squamous cell carcinoma receiving concurrent chemoradiotherapy. A cohort of 108 patients was recruited. Survival analysis showed that lower esophageal location of tumor, more advanced metastasis stage, and longer length of tumor were associated with poorer overall survival (adjusted P = 0.001, < 0.001, and 0.045, respectively), while the presence of complete/partial response to concurrent chemoradiotherapy was independently associated with better overall survival (adjusted P < 0.001). The GALNT14-rs9679162 “GG” genotype was associated with a lower rate of response (P = 0.014). Multivariate Cox-proportional hazards models also showed that the “GG” genotype was associated with a longer time to complete/partial response (adjusted P = 0.022), independent of leukocyte counts and gender. In conclusion, the presence of a complete/partial response to chemoradiotherapy was critical for advanced esophageal squamous cell carcinoma patients to achieve better overall survival. The GALNT14-rs9679162 “GG” genotype was associated with a longer time to complete/partial response of concurrent chemoradiotherapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16253

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma

Abstract